The head-to-head studies in this systematic review and meta-analysis did not identify any meaningful difference in the risk of serious infections, malignant neoplasms, or MACEs with JAK inhibitor vs TNF antagonist use across all IMIDs, with low overall incidence. This evidence concerns the gene TNF and cancer.